Drug Trial Radar · NCT07124559
A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
144
Planned (sponsor's estimate)
Start
Sep 28, 2026
Primary completion
Jun 26, 2028
Study completion Nov 15, 2028
Sponsor
- Sponsor type
- NIH
- Collaborators
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Mental Health (NIMH)
- First posted
- Aug 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 13 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to find the proposed dose of Rifapentine (RPT) taken once daily with Isoniazid (INH) for 28 days to prevent tuberculosis (TB). The study will take place at multiple locations and children under 13 years old will be divided into two groups: one group will include children without HIV, and the other group will include children with HIV who are on antiretroviral treatment. Up to 144 children will participate, and participants in each group will be followed for 24 weeks.
Conditions
- Tuberculosis
Interventions
RifapentineDrug
Dispersible Tablet administered orally
IsoniazidDrug
Dispersible Tablet administered orally
DolutegravirDrug
Tablets and Tablets for oral suspension administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Plasma concentration of Rifapentine (RPT) at specified time points among children with and without HIVTime frame: Through Day 28
- Area Under the Curve (AUC)(0-inf) of RPTTime frame: Through Day 28
- Maximum serum concentration (C(max)) of RPTTime frame: Through Day 28
- Half-life (t1/2) of RPTTime frame: Through Day 28
- Apparent oral clearance (CL/F) of RPTTime frame: Through Day 28
- Apparent oral volume of distribution (V/F) of RPTTime frame: Through Day 28
- Absorption rate (ka) of RPTTime frame: Through Day 28
- Trough serum concentration (C(trough)) of DTG (Cohort 2 only)Time frame: At study entry, Day 28 and Day 42
- CL/F of DTG (Cohort 2 only)Time frame: At study entry, Day 28 and Day 42
- Proportion of participants experiencing Adverse Events (AEs)Time frame: Through Day 28
- Proportion of participants experiencing Grade 3 or higher AEsTime frame: Through Day 28
- Proportion of participants experiencing Grade 2 or higher AEs assessed as related to 1HPTime frame: Through Day 28
- Proportion of participants experiencing Serious Adverse Events (SAEs) assessed as related to 1HPTime frame: Through Day 28
- Proportion of participants experiencing AEs assessed as related to 1HP that led to permanent discontinuation of the regimenTime frame: Through Day 28
Locations
11 sites in 6 countries. Site status is shown where the registry gives one.
Gaborone (Site ID: 12701)
Gaborone, Botswana · Recruiting
Molepolole CRS (Site ID: 12702)
Molepolole, Botswana · Recruiting
Les Centres GHESKIO (Site ID: 30022)
Port-au-Prince, Haiti · Not yet recruiting
Kenya Medical Research Institute/Walter Reed Project Clinical Research Center, Kericho CRS (Site ID: 5121)
Kericho, Kenya · Not yet recruiting
Chiangrai Prachanukroh Hospital (Site ID: 5116)
Chiang Rai, Thailand · Recruiting
Siriraj Hospital, Mahidol University NICHD CRS (Site ID: 5115)
Bangkok, Bangkoknoi, Thailand · Not yet recruiting
Baylor-Uganda CRS (Site ID: 31798)
Kampala, Uganda · Recruiting
MU-JHU Research Collaboration (MUJHU CARE LTD) CRS (Site ID: 30293)
Kampala, Uganda · Recruiting
St Mary's CRS (Site ID: 30303)
Chitungwiza, Zimbabwe · Not yet recruiting
Harare Family Care CRS (Site ID: 31890)
Harare, Zimbabwe · Not yet recruiting
Seke North CRS (Site ID: 30306)
Seke North, Chitungwiza, Zimbabwe · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.